| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Review |
1 Division of Medical Virology, Department of Pathology, University of Stellenbosch, Tygerberg 7505, South Africa
2 National Health Laboratory Services (NHLS), Tygerberg 7505, South Africa
Correspondence
Bizhan Romani
bizhan{at}sun.ac.za
 |
ABSTRACT |
|---|
|
Introduction |
|---|
). Viral proteins are known to compete with the host proteins thus disrupting the normal host protein–protein interaction network (Sodhi et al., 2004; Tournier & Quesnel-Hellmann, 2006). Molecular studies have revealed nearly 1500 interactions between human immunodeficiency virus type 1 (HIV-1) and human proteins, these interactions are catalogued in the HIV-1, Human Protein Interaction Database (Fu et al., 2009; Pinney et al., 2009; Ptak et al., 2008). Efforts to understand the interactions between viral and cellular gene products that together determine the host's susceptibility to infection and disease have led to significant new insights about HIV-1 (Samuel, 2006).
In addition to the structural genes (gag, pol and env), the HIV-1 genome contains four accessory (vif, vpr, vpu and nef) and two regulatory (tat and rev) genes, the products of which are responsible for establishing sophisticated interactions between the virus and human host (da Silva et al., 2006; Zuo et al., 2006). HIV-1 Tat is well-known as a transactivator protein that contributes to transactivation of viral and cellular genes (Ju et al., 2009; Mahlknecht et al., 2008; Nekhai et al., 2007). Tat is an early regulatory protein that has a variable length of 86–104 aa, encoded by two exons (Fig. 1). The first exon encodes the first 72 aa (Pugliese et al., 2005; Schwarze et al., 1999). Due to the variable length of Tat, its weight varies from 14 to 16 kDa. Incomplete forms of this viral protein (from 58 to 72 aa) may also be able to induce the biological affects of the full-length protein. A double splicing mechanism occurs after the transcription of tat mRNA. This is a post-transcriptional modification that consists of cutting of the tat mRNA and removal of unnecessary sequences. The process is followed by the joining together of nucleic acid sequences (Fanales-Belasio et al., 2009; Pugliese et al., 2005).
|
; Zheng et al., 2005). Studies of Tat-derived peptides have demonstrated that residues 48–60 from the basic domain (the protein transduction domain or PTD) account for the functional internalization into cells (Futaki et al., 2001; Schwarze et al., 2000) and that cellular heparan sulfate proteoglycans act as low-affinity cellular receptors for extracellular Tat (Tyagi et al., 2001). Mutational analysis of HIV-1 Tat has identified two important functional domains: an activation domain that mediates its interactions with cellular machinery and an arginine-rich region that is required for binding to the transactivation responsive element (TAR) RNA (Hwang et al., 2003). |
Role of Tat in synthesis of full-length viral transcripts |
|---|
; Richman et al., 2009; Wong et al., 2005; Yedavalli et al., 2003). A glance at these functions may suggest separate functions for one single protein. However, the thorough study of Tat suggests all of these functions are sequentially triggered as a cascade for a single purpose, namely, HIV-1 gene expression. In fact, HIV expression is limited by cellular barriers which inhibit effective mRNA transcription. The HIV-1 provirus overcomes these barriers through the action of its own activator, Tat (Pumfery et al., 2003). Tat recruits cellular proteins to relieve the repression of the viral long-terminal repeat (LTR), and thereby the viral promoter can induce the expression of viral genes (Richman et al., 2009).
In the absence of any stimulation, the integrated HIV-1 provirus remains silent in latently infected cells such as T cells, monocytes and macrophages. Expression of the viral genome is regulated by the enhancer and promoter elements contained within the HIV LTR located at the 5'end of the integrated HIV provirus (Fig. 1
) (Rohr et al., 2003). HIV-1 Tat interacts with several chromatin modifying complexes and histone modifying enzymes to relieve the virus LTR. Tat recruits various histone acetyltransferases (HATs), such as the CREB-binding protein (CBP)/p300 complex, to the HIV-1 promoter region, and thereby the nucleosomes on the promoter are acetylated by these enzymes (Fig. 2). Tat-induced acetylation of the nucleosomes by CBP/p300 relieves the repression of the LTR promoter such that the transcription by RNA polymerase II is not aborted and the enzyme efficiently transcribes the viral genes (Deng et al., 2000; Pumfery et al., 2003). In vitro studies have demonstrated that Tat changes the conformation of the CBP/p300 complex such that it can bind better to basal transcription factors such as the TATA-binding protein and the transcription factor IIB (Deng et al., 2000, 2001). It has also been shown that Lys-28 in the activation domain of Tat, which is essential for HIV-1 transcription and replication, is acetylated by the p300/CBP-associated factor (PCAF) (D'Orso & Frankel, 2009). Triggering the transcription factors suggests that Tat may influence the transcription machinery by helping the CBP/p300 complex to recruit new partners into the transcription machinery (Deng et al., 2000).
|
). However, in the absence of Tat or cellular activation signals, the efficiency of the bound RNA polymerase is dramatically reduced, resulting in the production of abortive short viral transcripts (Fig. 2a) (Pagans et al., 2005). Tat binds to an RNA stem–loop structure, called TAR, which is located at the 5' end of all initiated viral transcripts. Tat also recruits P-TEFb complex which is composed of cellular cyclin T1 and CDK9 proteins (Zhou et al., 2003). The P-TEFb complex phosphorylates serine residues in the C-terminal domain (CTD) of RNA polymerase II. These events potentiate RNA polymerase II to synthesize full-length HIV transcripts (Williams et al., 2006). Tat-induced serine phosphorylation of CTD by P-TEFb also stimulates the human capping enzyme, leading to capping of HIV-1 mRNAs (Zhou et al., 2003).
Besides the RNA polymerase II complex, the phosphorylation of additional transcription factors, including Sp1, CREB, the alpha subunit of eukaryotic initiation factor 2 (eIF2
) and NF-
B have also been reported to be triggered by Tat (Demarchi et al., 1999; Li et al., 2005; Rossi et al., 2006; Zauli et al., 2001). Tat has been indicated to influence the HIV-1 promoter by phosphorylation of Sp1. Three tandem repeats of Sp1-binding sites have been identified in HIV-1 LTR (Fig. 1). Sp1 plays a critical role in many cellular events by regulating the expression of cellular genes. Tat activates Sp1 by phosphorylation of this protein, and thereby Sp1 proteins bind to LTR to upregulate the HIV-1 promoter (Chang et al., 1994; Rossi et al., 2006). The interaction of Tat with the HIV-1 accessory protein Vpr has also been shown to enhance the transcriptional activity of the HIV-1 LTR. Co-transfection studies using HIV-1 LTR luciferase reporter plasmid and Tat-plus-Vpr-expression vector indicate superactivation of LTR by Tat and cyclin T1/CDK9 in the presence of wild-type Vpr. Results from protein–protein interaction studies have demonstrated that Vpr is associated with both Tat and cyclin T1 in cells expressing these proteins (Sawaya et al., 2000).
|
Tat-induced modulation of cellular gene expression |
|---|
; Stettner et al., 2009). For example, Tat has been shown to upregulate the expression levels of a number of cytokines, the HIV-1 co-receptor CCR5 and the interleukin-2 (IL-2) receptor (CD25) in HIV-1-infected cells (Mayol et al., 2007; Stettner et al., 2009; Zheng et al., 2005). Tat also downregulates several genes, such as the gene encoding major histocompatibility complex (MHC) class I (Matsui et al., 1996). The transactivating effects of Tat are not limited to HIV-1-infected cells because the extracellular Tat protein, released from virus-infected cells, is able to enter uninfected cells and exert its activity directly on responsive genes (Ju et al., 2009). The upregulation of cellular genes by Tat consequently induces additional effects, such as apoptosis induction and immunosuppression (Gupta et al., 2008; Poggi & Zocchi, 2006; Bannasser & Bahraoui, 2002; Zheng et al., 2005), which will be discussed later.
In vivo studies have shown that Tat deregulates the expression levels of several cytokines (Scala et al., 1994; Westendorp et al., 1994; Bannasser & Bahraoui, 2002). By using a vector expressing IL-6 under the control of the IL-6 promoter, it has been demonstrated that Tat transactivates the human IL-6 promoter (Scala et al., 1994). Ambrosino et al. (1997) have identified a short sequence at the 5' end of the IL-6 mRNA that is required for Tat to transactivate the IL-6 promoter. This sequence acquires a stem–loop structure and contains a UCU sequence that binds to Tat and is necessary for full transcription of IL-6 mRNA. Li et al. (2005) have examined the mechanism involved in Tat-induced cytokine dysregulation and found that Tat upregulates cytokine expression through protein kinase R (PKR) activation in primary blood monocytes. A recent study has demonstrated that subtype B and subtype C Tat protein exert differential cytokine modulating effects. The study showed that the expression of anti-inflammatory molecules including IL-4 and IL-10 is higher in Tat C-treated compared with Tat B-treated cultures of primary human monocytes. Conversely, subtype B Tat protein shows significant upregulation of pro-inflammatory cytokines, IL-6 and TNF-, as compared with subtype C Tat protein (Gandhi et al., 2009).
Matrix metalloproteinases (MMPs) can mediate the degradation of extracellular matrix proteins and also degrade components of the blood–brain barrier. The activity of MMPs is strictly regulated at the levels of gene expression. The dysregulation of MMP activity in HIV-infected individuals is associated with disease progression by influencing the integrity of the extracellular matrix. Recently, it has been shown that extracellular Tat upregulates the expression of MMP 9 via an NF-B-dependent pathway in astrocytes (Ju et al., 2009).
In addition to Tat protein, transfected TAR RNA has also been shown to attenuate the RNAi machinery in human cells (Bennasser et al., 2006). Recently, TAR miRNA has been implicated in the modulation of cellular gene expression. This miRNA is functional and may be involved in the regulation of the viral life cycle through suppression of viral transcription. The TAR mRNA is expressed at all stages of the viral life cycle and can be detected in latently infected cells. An in vitro study using TAR miRNA expression vector has shown that TAR miRNA protects infected cells from apoptosis and acts by downregulating cellular genes involved in apoptosis. The study also shows that the miRNA downregulates excision repair cross complementing group 1 (ERCC1) and intermediate-early response 3 (IER3), protecting the cell from apoptosis (Klase et al., 2009; Ouellet et al., 2008).
|
Tat-induced modulation of genes from non-HIV viruses |
|---|
; Stettner et al., 2009). In a number of carcinogenic viruses, such as human papillomavirus (HPV) and KS-associated herpesvirus (KSHV) this activation could result in neoplasia (Aoki & Tosato, 2004; Turner & Palefsky, 1998), this is discussed below.
Tat has been implicated in the stimulation of JC virus (JCV) which is the aetiological agent of progressive multifocal leukoencephalopathy. The virus causes demyelinating disease of the brain in HIV-infected individuals. Although HIV-1-induced immunosuppression is involved in infection of the brain by JCV, a direct association with HIV-1 Tat has also been established. Tat has been shown to activate the cytokine transforming growth factor (TGF)-β in HIV-1-infected cells and to stimulate JCV gene transcription and DNA replication in oligodendrocytes, myelin producing cells of the central nervous system (CNS). In vitro studies have indicated that Tat stimulates transcription from both early and late gene promoters of JCV (Stettner et al., 2009).
Tat has been demonstrated to stimulate polyomavirus BK (BKV) (Gorrill et al., 2006), which rarely causes disease. Many people who are infected with BKV are asymptomatic. However, the virus is a serious problem for immunocompromised patients, such as HIV patients (Miller et al., 2009). In vitro experiments have shown that Tat activates BKV by inducing binding of NF-B to a B motif within the early promoter of the virus (BKVE). A sequence within the 5'-untranslated region of BKVE transcripts (BKVE-TAR) has been identified that is identical to the HIV-1 TAR. Interestingly, Tat has been shown to bind to BKVE-TAR to stimulate transcription of the viral genes. In vitro results suggest that Tat stimulates BKVE transcription by a dual mechanism (Gorrill et al., 2006).
|
Role of Tat in HIV-1 reverse transcription |
|---|
). However, the viral RNA of the Tat-mutated viruses appeared as partially degraded molecules on agarose gels and not in dimeric form as found within wild-type virions. It has been reported that the conformation of virion RNA is critical for reverse transcription, particularly for the first-strand transfer. It is believed that the degraded nature of the RNA in Tat-mutated virions accounts, at least in part, for the failure of this RNA to undergo efficient reverse transcription in infected cells. It is also possible that the low levels of Tat incorporation into HIV-1 virions may not be detected by currently available techniques. It has been suggested that as few as two molecules of Tat may be incorporated into virions by binding to the two copies of HIV-1 genomic RNA. Hence, Tat can conceivably be associated with the reverse transcription complex and directly participate in reverse transcription following infection of target cells (Bres et al., 2002; Liang & Wainberg, 2002).
In vitro studies have shown that wild-type Tat can increase viral infectivity by suppressing the RT at late stages of the viral life cycle. Tat has been suggested to inhibit reverse transcription in order to prevent the premature synthesis of potentially deleterious viral DNA products. Tat has also been reported to possess an RNA-annealing activity which enables it to promote the placement of tRNA onto viral RNA. The viral nucleocapsid (NC) protein has also been documented to promote the annealing of tRNALys as a primer for reverse transcription. The RNA-annealing activity of Tat suggests a functional homology between Tat and NC. Tat appears to play at least two different roles in viral reverse transcription: suppression of DNA polymerization and placement of tRNA onto viral RNA. The first activity may contribute to the efficiency of reverse transcription of the viral genome as well as to the enhanced production of infectious viral particles. The second activity may play a potential role for NC in the displacement of Tat during viral maturation (Kameoka et al., 2002).
|
Immune suppression by Tat |
|---|
have shown that Tat suppresses gp120-specific T-cell response in an IL-10-dependent manner and the immunosuppressive effect of Tat is not observed in IL-10-deficient mice. Although they have suggested that the immunosuppressive effect of Tat is mediated through IL-10, it seems that Tat may adopt several strategies to suppress the immune system of HIV-infected individuals (Barton et al., 1996; Gallo, 1999; Miura et al., 2003; Poggi & Zocchi, 2006; Zheng et al., 2005).
In vitro studies have demonstrated that Tat could inhibit interferon-induced nitric oxide synthase gene activity in macrophages. The inhibitory effect of Tat on the production of nitric oxide by host macrophages renders the host vulnerable to infections, since nitric oxide provides the first line of defence against opportunistic pathogens (Barton et al., 1996). Tat also activates alpha interferon (IFN-) production in macrophages. A high level of IFN- production, which is mediated by Tat, may be involved in induction of immune suppressive effects since overproduction of IFN- could result in anti-proliferative effects (Gallo, 1999). Although IFNs are known as antiviral agents, Zaguri et al. (1998) have shown the involvement of overexpression of IFN- in the immunosuppression of uninfected T cells. The inhibitory effects of Tat on MHC I expression also suggest another mechanism for induction of immune suppression by Tat. Since MHC I presents intracellular antigens to CD8+ T cells, downregulation of MHC I could seriously affect CD8+ T cell-associated immune activation and immune responsiveness in general (Dalakas, 2006; Matsui et al., 1996; Mayol et al., 2007).
Tat-induced apoptosis may also be involved in the immunosuppressive activities of Tat. The upregulation of TGF-β transcription by Tat has been claimed to contribute to immunosuppression in AIDS (Poggi & Zocchi, 2006). TGF-β has been reported to induce apoptosis in several cell types through AP-1-dependent activation of the src homology 2 (SH2)-domain containing inositol-5-phosphatase (Licona-Limón & Soldevila, 2007; Tarasenko et al., 2007). The upregulation of TGF-β by Tat reduces anti-apoptotic proteins and thereby renders immune cells vulnerable to apoptosis. The outcome of this event could be the induction of immunosuppression (Poggi & Zocchi, 2006).
|
Apoptosis induction by Tat |
|---|
; Ruwanpura et al., 2008). In vitro studies have shown that HIV-1 Tat is able to induce the intrinsic pathway of apoptosis in a number of human cell lines. The results of these studies suggest that Tat promotes apoptosis during HIV-1 infection (Giacca, 2005; Kim et al., 2003; Park et al., 2001) although other proteins of HIV-1 (Vpr and gp120) have also been shown to induce apoptosis (Ramalingam et al., 2008; Romani & Engelbrecht, 2009; Vashistha et al., 2009). Extracellular Tat, produced by adjacent infected macrophages, microglia or astrocytes, can interact with the low density lipoprotein receptor-related protein (LRP) on the surfaces of neurons to enter cells by endocytosis. Extracellular Tat has been shown to induce neuronal death by binding to the LRP. Accumulating evidence suggests that extracellular Tat plays an important role in neuronal apoptosis induction, which is associated with the neurotoxic effects of Tat (Kim et al., 2008; Wong et al., 2005).
A link between microtubule polymerization and the pro-apoptotic effect of Tat has been suggested since the interaction of Tat with both non-polymerized subunits of microtubules (β-tubulin dimers) and polymerized microtubules, leads to mitochondrial induction of apoptosis (Fig. 3) (de Mareuil et al., 2005; Giacca, 2005; Vendeville et al., 2004). The functional consequence of this interaction is microtubule stabilization and the consequent prevention of microtubule depolymerization. Since cells are dynamic units requiring constant polymerization and depolymerization of microtubules, this change in microtubule stabilization can act as a powerful inducer of the intrinsic pathway of cellular apoptosis (Campbell et al., 2004; de Mareuil et al., 2005; Giunta et al., 2009).
|
; Epie et al., 2005). Interestingly, the ability of different Tat variants to enhance microtubule polymerization correlates with their capacity to induce apoptosis. It has been shown that Tat interference with the microtubule polymerization results in mitochondrial membrane permeability. Similar to microtubule damaging agents, the pro-apoptotic effect of Tat correlates with the induction of cytochrome c release from mitochondria, a critical event triggering apoptosis (Giacca, 2005).
Tat has also been shown to upregulate tumour necrosis factor-related apoptosis-induced ligand (TRAIL), and caspases-3 and -8 in human monocytes (Miura et al., 2003; Zheng et al., 2005). TRAIL is a member of death-inducing ligands of the tumour necrosis factor (TNF) family and activates caspases-3 and -8, resulting in apoptosis (Perez-Cruz et al., 2007; Siegelin et al., 2009; Subramanian et al., 2009). Tat also upregulates Fas, Fas ligand (FasL/CD95L) and TNF- in human astrocytes (Chauhan et al., 2003). The Fas/FasL system comprises an important mechanism for regulating apoptotic cell death (Inoue et al., 2007; Nakajima et al., 2008). The ability of Tat to recruit so many apoptosis-inducing proteins suggests that Tat induces apoptosis by adopting multiple mechanisms (Dabrowska et al., 2008; Zhao et al., 2007).
The interaction between Tat and the microtubular network may explain the occurrence of neuropathogenesis associated with the progression of HIV-1 infection, since many human neurodegenerative conditions are accompanied by a reorganization of the neuronal cytoskeleton (Drewes et al., 1998). The induction of the microtubule stabilization by Tat could also be a potentially pro-apoptotic mechanism along with the recruitment of other apoptosis-inducing mechanisms, such as the upregulation of Fas, FasL, TRAIL, Bax and caspase-8 (Chauhan et al., 2003; Giacca, 2005).
|
Apoptosis inhibition by Tat |
|---|
; Mischiati et al., 1999). Tat discriminately acts on different cell types in a concentration-dependent manner such that it has been suggested that the establishment of HIV-1 latent infection could be due to the low levels of Tat production (Deregibus et al., 2002; Gallo, 1999).
Tat has been implicated in the upregulation of B-cell lymphoma 2 (BCL-2), an anti-apoptotic protein, in monocytes isolated from peripheral blood. Extracellular Tat proteins can be taken up by monocytes, and thereby induce biological effects. Since BCL-2 inhibits apoptosis induction by TRAIL, the upregulation of BCL-2 by Tat protects human monocytes from apoptosis (Zhang et al., 2002; Zheng et al., 2007). The anti-apoptotic activities of Tat may account for the establishment of HIV-1 latency in human cells (Deregibus et al., 2002; Zheng et al., 2007). The role of Tat in apoptosis becomes more complicated in the CNS. Despite the adverse effects of Tat protein on the CNS, it has been shown that Tat binds to Bcl-XL, an anti-apoptotic member of the Bcl-2 family, and forms a complex capable of inhibiting apoptosis in neuronal cells both in vitro and in vivo (Pugliese et al., 2005).
Cantaluppi et al. (2001) have shown that Tat, in a dose-dependent manner, protects Kaposi's sarcoma (KS) cell lines and human umbilical vein endothelial cells from apoptosis induced by vincristine or serum starvation, respectively. Their results indicate that the anti-apoptotic activity of Tat was independent on the modulation of Fas or Bax expression. In contrast, Tat upregulated Bcl-XL and induced a relevant decrease in caspase-3 activity. Deregibus et al. (2002) have shown that Tat protects vincristine-treated KS cells from apoptosis and from the downregulation of several anti-apoptotic genes such as akt-1, akt-2, bcl2 and bcl-xL. Novel studies have shown that TAR miRNA also downregulates cellular genes involved in apoptosis. TAR miRNA has been shown to protect cells from apoptosis by downregulating ERCC1 and IER3. ERCC1 is involved in the detection and base excision repair of damaged nucleotides. IER3 is upregulated after cellular insult and has been shown to be required for the induction of apoptosis after DNA damage (Klase et al., 2009). The anti-apoptotic property of TAR may explain how infected cells can inhibit apoptosis, while extracellular Tat induces apoptosis in bystander cells.
|
Tat and AIDS-associated cancer |
|---|
; Bowater et al., 2009). AIDS is accompanied by a significant increase in the incidence of neoplasms. Several reasons have been proposed for this phenomenon, including immunodeficiency, oncogenic DNA viruses and HIV-1 Tat. It has been suggested that the Tat-induced DNA repair deficiencies may be involved in the development of AIDS-associated cancer (Nunnari et al., 2008).
Accumulating evidence indicates that cancer patients with HIV-1/AIDS have more severe tissue reactions and often develop cutaneous toxic effects when subjected to radiotherapy. In vitro studies using Tat-expressing cell lines suggest that Tat affects cellular responses to ionizing radiation. The expression of Tat protein in human cell lines may increase the proliferation activity of the cells but decreases their capacity to repair radiation-induced DNA double-stranded breaks (Sun et al., 2006).
An increased oxidative stress level is observed in AIDS patients. A relationship between Tat-induced damage and redox alteration in non-intestinal epithelia has been observed. In vitro studies have indicated that exposure to Tat induces oxidative stress in cell cultures which can be partially inhibited by antioxidants (Penza et al., 2008). The role of Tat in the induction of oxidative stress will be discussed in more detail in the next section.
Tat is released by acutely infected HIV T cells and the extracellular Tat promotes the adhesion, migration, invasion and growth of KS and endothelial cells activated with T helper-1 type inflammatory cytokines. In HIV-1-infected individuals, KS is more frequent and severe. Several studies have suggested this severity is due to the HIV-1 Tat which acts synergistically with basic fibroblast growth factor (bFGF) to induce angiogenesis, vascular permeability and oedema. These latter activities are the main processes involved in KS progression (Toschi et al., 2006). The abundance of KS in HIV-infected individuals has also been attributed to the role of Tat in facilitating the replication of KSHV. AIDS-KS is one of the most common AIDS-associated malignancies in HIV-infected homosexual males. KSHV has been described as the aetiological agent of KS. HIV-1 Tat has been implicated to promote KSHV transmission. Tat enhances the entry of KSHV into endothelial and other cells. It has been suggested that Tat could cause KS by facilitating the cells to infection by the KSHV (Aoki & Tosato, 2004; Tian et al., 2008). An increase in the prevalence of anogenital human papillomavirus (HPV) infection has also been observed in HIV-infected individuals. The virus represents more aggressive behaviour of invasive cervical cancer in these patients. Tat has been shown to transactivate the HPV LCR, stimulating the invasion of the virus which is a potential carcinogen (Nyagol et al., 2006; Turner & Palefsky, 1998).
|
Role of Tat in oxidative stress, neurotoxicity and HIV-associated dementia (HAD) |
|---|
). Oxidative stress has been demonstrated both in the brain and in cerebrospinal fluid (CSF) of HAD patients (Turchan et al., 2003). The results of some studies suggest that Tat is a potential contributor to HIV-1 dementia (Haughey & Mattson, 2002; Wallace et al., 2005). Tat increases intracellular Ca2+ in neurons, followed by mitochondrial calcium uptake which results in the generation of ROS, activation of caspases and eventually apoptosis of neurons. Tat can be transported efficiently across the intact blood–brain barrier. The mRNA levels for Tat have been reported to be elevated in the brain extracts from HIV-1 dementia patients. The Tat sequences from brains of these patients are mutated with glutamate substitutions in the second exon. These mutations may decrease the ability of Tat to enter cells, thus increasing the concentrations of the extracellular Tat proteins and possibly associated neurotoxic effects on the cells. Brain tissues are particularly susceptible to Tat toxicity (Pocernich et al., 2005).
Tat has been reported to upregulate the prostate apoptosis response-4 (Par-4) expression in neurons to induce apoptosis by oxidative stress, which is followed by mitochondrial dysfunction and perturbation of Ca2+-regulated channels and glutamate receptors. Evidently, Tat plays an important role during neuropathogenesis, both as an intracellular and extracellular mediator of neurotoxicity (Wong et al., 2005). Price et al. (2005) have demonstrated that Tat causes oxidative stress in immortalized rat brain endothelial cells by a time-dependent decrease in the levels of intracellular glutathione and a time-dependent increase in the levels of the oxidized form of glutathione (GSSG). Glutathione is a critical factor responsible for maintaining the cellular redox status and antioxidant defence in endothelial cells against oxidative stress. As a result of the oxidative stress induced by Tat, glutathione is oxidized to GSSG.
Tat induces its neurotoxicity through interaction with the neuronal cell membrane (Cheng et al., 1998). Tat has been shown to specifically bind to rat brain synaptosomal membranes with moderate affinity (Pocernich et al., 2005). Tat has been shown to enter neurons through binding to the LRP on neurons (Liu et al., 2000). Tat has also been implicated in the induction of neurological dysfunction at sites distant from that of viral replication by neuronal transport. Extracellular Tat can be transferred from the brain to the spinal cord by CSF, which explains how Tat can cause neurotoxicity and dysfunction at sites distant from viral replication (Pocernich et al., 2005).
|
Concluding remarks |
|---|
; Nyagol et al., 2006; Turner & Palefsky, 1998). It seems logical to hypothesize that in addition to HIV-1-induced immunosuppression, the transactivation of cellular and viral genes by Tat alters conditions in favour of certain pathogens, as well as neoplastic disorders. However, the biological significance of supporting opportunistic pathogens by Tat remains to be elucidated.
Identification of the critical role of Tat in transcription of the HIV-1 genome has provoked a number of studies which focus on Tat as a target for antiretroviral drugs (Daelemans et al., 2000; Melekhovets et al., 2001; Turpin, 2003). The interaction of Tat with TAR is considered a suitable target for the chemotherapy of HIV infection, because an inhibitor of the Tat–TAR interaction may have the potential to maintain the virus in a latent state. A basic peptoid oligomer of nine residues, known as CGP64222, can effectively compete with Tat for binding to TAR and block HIV-1 replication in peripheral blood lymphocytes (Chen et al., 2009; Daelemans et al., 2000). Several studies have developed short TAR RNA decoy molecules which can compete with TAR for binding to Tat (Liang & Wainberg, 2002). The ability of Tat to cross the cellular membrane has also been addressed as a mechanism to deliver new drugs, polypeptides or antibodies to target cells. Several studies have shown that different substances conjugated to Tat or the nuclear import sequences of Tat can cross the cellular membrane (Hu et al., 2006; Schwarze & Dowdy, 2000). These findings may have important therapeutic implications for the future.
Tat could have different effects on different cells, thereby the modulating effects of Tat on gene expression need to be addressed in different cells and tissues. An understanding of the mechanism by which HIV-1 Tat modulates gene expression in HIV-1-infected cells, may reveal the detailed mechanism by which HIV suppresses the immune system. In addition the study of the interactions of Tat with the CNS may lead to novel therapies to control inflammatory processes during the development of HIV-induced neurological diseases. There are still unanswered questions about Tat that need to be addressed. For example, what amounts of Tat are required in different cells to sustain HIV-1 replication and what factors define the amount of Tat present in cells? Is the concentration of Tat for binding to tubulin and exerting its pro-apoptotic effects compatible with its concentration in the infected cells to diffuse to neighbouring cells? Answers to these and other questions will hopefully be revealed through current research, leading to a better and more comprehensive understanding of this protein.
|
REFERENCES |
|---|
Ammosova, T., Berro, R., Jerebtsova, M., Jackson, A., Charles, S., Klase, Z., Southerland, W., Gordeuk, V. R., Kashanchi, F. & Nekhai, S. (2006). Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. Retrovirology 3, 78[CrossRef][Medline]
Aoki, Y. & Tosato, G. (2004). HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. Blood 104, 810–814.
Barton, C. H., Biggs, T. E., Mee, T. R. & Mann, D. A. (1996). The human immunodeficiency virus type 1 regulatory protein Tat inhibits interferon-induced iNos activity in a murine macrophage cell line. J Gen Virol 77, 1643–1647.
Bennasser, Y. & Bahraoui, E. (2002). HIV-1 Tat protein induces interleukin-10 in human peripheral blood monocytes: involvement of protein kinase C-βII and -
. FASEB J 16, 546–554.
Bennasser, Y., Yeung, M. L. & Jeang, K.-T. (2006). HIV-1 TAR RNA subverts RNA interference in transfected cells through sequestration of TAR RNA-binding protein, TRBP. J Biol Chem 281, 27674–27678.
Bernard-Gallon, D., Bosviel, R., Delort, L., Fontana, L., Chamoux, A., Rabiau, N., Kwiatkowski, F., Chalabi, N., Satih, S. & Bignon, Y. J. (2008). DNA repair gene ERCC2 polymorphisms and associations with breast and ovarian cancer risk. Mol Cancer 7, 36[CrossRef][Medline]
Bowater, R. P., Borts, R. H. & White, M. F. (2009). DNA damage: from causes to cures. Biochem Soc Trans 37, 479–481.[CrossRef][Medline]
Bres, V., Kiernan, R., Emiliani, S. & Benkirane, M. (2002). Tat acetyl-acceptor lysines are important for human immunodeficiency virus type-1 replication. J Biol Chem 277, 22215–22221.
Campbell, G. R., Pasquier, E., Watkins, J., Bourgarel-Rey, V., Peyrot, V., Esquieu, D., Barbier, P., de-Mareuil, J., Braguer, D. & other authors (2004). The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis. J Biol Chem 279, 48197–48204.
Cantaluppi, V., Biancone, L., Boccellino, M., Doublier, S., Benelli, R., Carlone, S., Albini, A. & Camussi, G. (2001). HIV type 1 Tat protein is a survival factor for Kaposi's sarcoma and endothelial cells. AIDS Res Hum Retroviruses 17, 965–976.[CrossRef][Medline]
Chang, P. Y., Stellrecht, K., Melana, S. & Pogo, B. G. T. (1994). Elements in the long terminal repeat of HIV-1 that interact with nuclear extracts from Jurkat cells persistently infected with vaccinia virus. Virus Res 34, 127–138.[CrossRef][Medline]
Chauhan, A., Turchan, J., Pocernich, C., Bruce-Keller, A., Roth, S., Butterfield, D. A., Major, E. O. & Nath, A. (2003). Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J Biol Chem 278, 13512–13519.
Chen, S., Chen, R., He, M., Pang, R., Tan, Z. & Yang, M. (2009). Design, synthesis, and biological evaluation of novel quinoline derivatives as HIV-1 Tat–TAR interaction inhibitors. Bioorg Med Chem 17, 1948–1956.[CrossRef][Medline]
Cheng, J., Nath, A., Knudsen, B., Hochman, S., Geiger, J. D., Ma, M. & Magnuson, D. S. (1998). Neuronal excitatory properties of human immunodeficiency virus type 1 Tat protein. Neuroscience 82, 97–106.[CrossRef][Medline]
D'Orso, I. & Frankel, A. D. (2009). Tat acetylation modulates assembly of a viral-host RNA–protein transcription complex. Proc Natl Acad Sci U S A 106, 3101–3106.
da Silva, F. H., Dalberto, T. P. & Nardi, N. B. (2006). Beyond retrovirus infection: HIV meets gene therapy. Genet Mol Biol 29, 367–379.
Dabrowska, A., Kim, N. & Aldovini, A. (2008). Tat-induced FOXO3a is a key mediator of apoptosis in HIV-1-infected human CD4+ T lymphocytes. J Immunol 181, 8460–8477.
Daelemans, D., Schols, D., Witvrouw, M., Pannecouque, C., Hatse, S., van-Dooren, S., Hamy, F., Klimkait, T., de-Clercq, E. & VanDamme, A. M. (2000). A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Mol Pharmacol 57, 116–124.
Dalakas, M. C. (2006). Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromuscul Disord 16, 223–236.[CrossRef][Medline]
de Mareuil, J., Carre, M., Barbier, P., Campbell, G. R., Lancelot, S., Opi, S., Esquieu, D., Watkins, J. D., Prevot, C. & other authors (2005). HIV-1 Tat protein enhances microtubule polymerization. Retrovirology 2, 5[CrossRef][Medline]
Demarchi, F., Gutierrez, M. I. & Giacca, M. (1999). Human immunodeficiency virus type 1 Tat protein activates transcription factor NF-B through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR. J Virol 73, 7080–7086.
Deng, L., de-la-Fuente, C., Fu, P., Wang, L., Donnelly, R., Wade, J. D., Lambert, P., Li, H., Lee, C. G. & Kashanchi, F. (2000). Acetylation of HIV-1 Tat by CBP/P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones. Virology 277, 278–295.[CrossRef][Medline]
Deng, L., Wang, D., de-la-Fuente, C., Wang, L., Li, H., Lee, C. G., Donnelly, R., Wade, J. D., Lambert, P. & Kashanchi, F. (2001). Enhancement of the p300 HAT activity by HIV-1 Tat on chromatin DNA. Virology 289, 312–326.[CrossRef][Medline]
Deregibus, M. C., Cantaluppi, V., Doublier, S., Brizzi, M. F., Deambrosis, I., Albini, A. & Camussi, G. (2002). HIV-1-Tat protein activates phosphatidylinositol 3-kinase/AKT-dependent survival pathways in Kaposi's sarcoma cells. J Biol Chem 277, 25195–25202.
Drewes, G., Ebneth, A. & Mandelkow, E. M. (1998). MAPs, MARKs and microtubule dynamics. Trends Biochem Sci 23, 307–311.[CrossRef][Medline]
Epie, N., Ammosova, T., Sapir, T., Voloshin, Y., Lane, W. S., Turner, W., Reiner, O. & Nekhai, S. (2005). HIV-1 Tat interacts with LIS1 protein. Retrovirology 2, 6[CrossRef][Medline]
Evans, P., Dampier, W., Ungar, L. & Tozeren, A. (2009). Prediction of HIV-1 virus-host protein interactions using virus and host sequence motifs. BMC Med Genomics 2, 27[CrossRef][Medline]
Fanales-Belasio, E., Moretti, S., Fiorelli, V., Tripiciano, A., Cossut, M. R. P., Scoglio, A., Collacchi, B., Nappi, F., Macchia, I. & other authors (2009). HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. J Immunol 182, 2888–2897.
Ferrari, A., Pellegrini, V., Arcangeli, C., Fittipaldi, A., Giacca, M. & Beltram, F. (2003). Caveolae-mediated internalization of extracellular HIV-1 Tat fusion proteins visualized in real time. Mol Ther 8, 284–294.[CrossRef][Medline]
Fu, W., Sanders-Beer, B. E., Katz, K. S., Maglott, D. R., Pruitt, K. D. & Ptak, R. G. (2009). Human immunodeficiency virus type 1, human protein interaction database at NCBI. Nucleic Acids Res 37, D417
Futaki, S., Suzuki, T., Ohashi, W., Yagami, T., Tanaka, S., Ueda, K. & Sugiura, Y. (2001). Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276, 5836–5840.
Gallo, R. C. (1999). Tat as one key to HIV-induced immune pathogenesis and Tat toxoid as an important component of a vaccine. Proc Natl Acad Sci U S A 96, 8324–8326.
Gandhi, N., Saiyed, Z., Thangavel, S., Rodriguez, J., Rao, K. V. K. & Nair, M. P. N. (2009). Differential effects of HIV type 1 clade B and clade C Tat protein on expression of proinflammatory and anti-inflammatory cytokines by primary monocytes. AIDS Res Hum Retroviruses 25, 691–699.[CrossRef][Medline]
Giacca, M. (2005). HIV-1 Tat, apoptosis and the mitochondria: a tubulin link? Retrovirology 2, 7[CrossRef][Medline]
Giunta, B., Hou, H., Zhu, Y., Rrapo, E., Tian, J., Takashi, M., Commins, D., Singer, E., He, J. & other authors (2009). HIV-1 Tat contributes to Alzheimer's disease-like pathology in PSAPP mice. Int J Clin Exp Pathol 2, 433–443.[Medline]
Gorrill, T., Feliciano, M., Mukerjee, R., Sawaya, B. E., Khalili, K. & White, M. K. (2006). Activation of early gene transcription in polyomavirus BK by human immunodeficiency virus type 1 Tat. J Gen Virol 87, 1557–1566.
Gupta, S., Boppana, R., Mishra, G. C., Saha, B. & Mitra, D. (2008). HIV-1 Tat suppresses gp120-specific T cell response in IL-10-dependent manner. J Immunol 180, 79–88.
Harrich, D., Ulich, C., Garcia-Martinez, L. & Gaynor, R. B. (1997). Tat is required for efficient HIV-1 reverse transcription. EMBO J 16, 1224–1235.[CrossRef][Medline]
Haughey, N. J. & Mattson, M. P. (2002). Calcium dysregulation and neuronal apoptosis by the HIV-1 proteins Tat and gp120. J Acquir Immune Defic Syndr 31, S55–S61.[Medline]
Hu, M., Wang, J., Chen, P. & Reilly, R. M. (2006). HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1. Bioconjug Chem 17, 1280–1287.[CrossRef][Medline]
Hwang, S., Tamilarasu, N., Kibler, K., Cao, H., Ali, A., Ping, Y. H., Jeang, K. T. & Rana, T. M. (2003). Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication. J Biol Chem 278, 39092–39103.
Inoue, Y., Asanuma, T., Smith, N., Saunders, D., Oblander, J., Kotake, Y., Floyd, R. A. & Towner, R. A. (2007). Modulation of Fas-FasL related apoptosis by PBN in the early phases of choline deficient diet-mediated hepatocarcinogenesis in rats. Free Radic Res 41, 972–980.[CrossRef][Medline]
Ju, S. M., Song, H. Y., Lee, J. A., Lee, S. J., Choi, S. Y. & Park, J. (2009). Extracellular HIV-1 Tat up-regulates expression of matrix metalloproteinase-9 via a MAPK-NF-B dependent pathway in human astrocytes. Exp Mol Med 41, 86–93.[CrossRef][Medline]
Kameoka, M., Morgan, M., Binette, M., Russell, R. S., Rong, L., Guo, X., Mouland, A., Kleiman, L., Liang, C. & Wainberg, M. A. (2002). The Tat protein of human immunodeficiency virus type 1 (HIV-1) can promote placement of tRNA primer onto viral RNA and suppress later DNA polymerization in HIV-1 reverse transcription. J Virol 76, 3637–3645.
Kim, T. A., Avraham, H. K., Koh, Y. H., Jiang, S., Park, I. W. & Avraham, S. (2003). HIV-1 Tat-mediated apoptosis in human brain microvascular endothelial cells. J Immunol 170, 2629–2637.
Kim, H. J., Martemyanov, K. A. & Thayer, S. A. (2008). Human immunodeficiency virus protein Tat induces synapse loss via a reversible process that is distinct from cell death. J Neurosci 28, 12604–12613.
Klase, Z., Winograd, R., Davis, J., Carpio, L., Hildreth, R., Heydarian, M., Fu, S., McCaffrey, T., Meiri, E. & other authors (2009). HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression. Retrovirology 6, 18[CrossRef][Medline]
Li, J. C. B., Lee, D. C. W., Cheung, B. K. W. & Lau, A. S. Y. (2005). Mechanisms for HIV Tat upregulation of IL-10 and other cytokine expression: kinase signaling and PKR-mediated immune response. FEBS Lett 579, 3055–3062.[CrossRef][Medline]
Liang, C. & Wainberg, M. A. (2002). The role of Tat in HIV-1 replication: an activator and/or a suppressor? AIDS Rev 4, 41–49.[Medline]
Licona-Limón, P. & Soldevila, G. (2007). The role of TGF-β superfamily during T cell development: new insights. Immunol Lett 109, 1–12.[CrossRef][Medline]
Liu, Y., Jones, M., Hingtgen, C. M., Bu, G., Laribee, N., Tanzi, R. E., Moir, R. D., Nath, A. & He, J. J. (2000). Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat Med 6, 1380–1387.[CrossRef][Medline]
Mahlknecht, U., Dichamp, I., Varin, A., Lint, C. V. & Herbein, G. (2008). NF-B-dependent control of HIV-1 transcription by the second coding exon of Tat in T cells. J Leukoc Biol 83, 718–727.
Matsui, M., Warburton, R. J., Cogswell, P. C., Baldwin, A. S. & Frelinger, J. A. (1996). Effects of HIV-1 Tat on expression of HLA class I molecules. J Acquir Immune Defic Syndr Hum Retrovirol 11, 233–240.[Medline]
Mayol, K., Munier, S., Beck, A., Verrier, B. & Guillon, C. (2007). Design and characterization of an HIV-1 Tat mutant: inactivation of viral and cellular functions but not antigenicity. Vaccine 25, 6047–6060.[CrossRef][Medline]
Melekhovets, Y., Ramezani, A., Kyriakopoulou, L. & Joshi, S. (2001). Tat-RNase H and its use in HIV gene therapy. Gene Ther Mol Biol 6, 69–77.
Miller, M. A., Weibel, C., Ferguson, D., Landry, M. L. & Kahn, J. S. (2009). WU polyomavirus in patients infected with HIV or hepatitis C virus, Connecticut, USA, 2007. Emerg Infect Dis
Mischiati, C., Pironi, F., Milani, D., Giacca, M., Mirandola, P., Capitani, S. & Zauli, G. (1999). Extracellular HIV-1 Tat protein differentially activates the JNK and ERK/MAPK pathways in CD4 T cells. AIDS 13, 1637–1645.[CrossRef][Medline]
Miura, Y., Koyanagi, Y. & Mizusawa, H. (2003). TNF-related apoptosis-inducing ligand (TRAIL) induces neuronal apoptosis in HIV-encephalopathy. J Med Dent Sci 50, 17–25.[Medline]
Nakajima, H., Mizuta, N., Fujiwara, I., Sakaguchi, K., Ogata, H., Magae, J., Yagita, H. & Koji, T. (2008). Blockade of the Fas/Fas ligand interaction suppresses hepatocyte apoptosis in ischemia-reperfusion rat liver. Apoptosis 13, 1013–1021.[CrossRef][Medline]
Nekhai, S., Jerebtsova, M., Jackson, A. & Southerland, W. (2007). Regulation of HIV-1 transcription by protein phosphatase 1. Curr HIV Res 5, 3–9.[CrossRef][Medline]
Nunnari, G., Smith, J. A. & Daniel, R. (2008). HIV-1 Tat and AIDS-associated cancer: targeting the cellular anti-cancer barrier? J Exp Clin Cancer Res 27, 3[CrossRef][Medline]
Nyagol, J., Leucci, E., Onnis, A., Falco, G. D., Tigli, C., Sanseverino, F., Torriccelli, M., Palummo, N., Pacenti, L. & other authors (2006). The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesis. Cancer Biol Ther 5, 684–690.[Medline]
Ouellet, D. L., Plante, I., Landry, P., Barat, C., Janelle, M. E., Flamand, L., Tremblay, M. J. & Provost, P. (2008). Identification of functional microRNAs released through asymmetrical processing of HIV-1 TAR element. Nucleic Acids Res 36, 2353–2365.
Pagans, S., Pedal, A., North, B. J., Kaehlcke, K., Marshall, B. L., Dorr, A., Hetzer-Egger, C., Henklein, P., Frye, R. & other authors (2005). SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol 3, E41[CrossRef][Medline]
Paquette, J. C., Guerin, P. J. & Gauthier, E. R. (2005). Rapid induction of the intrinsic apoptotic pathway by L-glutamine starvation. J Cell Physiol 202, 912–921.[CrossRef][Medline]
Park, I. W., Ullrich, C. K., Schoenberger, E., Ganju, R. K. & Groopman, J. E. (2001). HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation. J Immunol 167, 2766–2771.
Penza, M., Buccigrossi, V., Giannattasio, A., Marco, G. D., Esposito, C., Polito, G., Squeglia, V., Assante, L. R., Ambrosio, R. & Guarino, A. (2008). HIV-1 transactivator factor (Tat) induces damage through a redox mechanism in human intestinal epithelial cells. Dig Liver Dis 40, A97[CrossRef]
Perez-Cruz, I., Cárcamo, J. M. & Golde, D. W. (2007). Caspase-8 dependent trail-induced apoptosis in cancer cell lines is inhibited by vitamin C and catalase. Apoptosis 12, 225–234.[CrossRef][Medline]
Pinney, J. W., Dickerson, J. E., Fu, W., Sanders-Beer, B. E., Ptak, R. G. & Robertson, D. L. (2009). HIV-host interactions: a map of viral perturbation of the host system. AIDS 23, 549–554.[CrossRef][Medline]
Pocernich, C. B., Sultana, R., Mohmmad-Abdul, H., Nath, A. & Butterfield, D. A. (2005). HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations. Brain Res Brain Res Rev 50, 14–26.[CrossRef][Medline]
Poggi, A. & Zocchi, M. R. (2006). HIV-1 Tat triggers TGF-β production and NK cell apoptosis that is prevented by pertussis toxin B. Clin Dev Immunol 13, 369–372.[CrossRef][Medline]
Price, T. O., Ercal, N., Nakaoke, R. & Banks, W. A. (2005). HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells. Brain Res 1045, 57–63.[Medline]
Ptak, R. G., Fu, W., Sanders-Beer, B. E., Dickerson, J. E., Pinney, J. W., Robertson, D. L., Rozanov, M. N., Katz, K. S., Maglott, D. R. & Pruitt, K. D. (2008). Cataloguing the HIV type 1 human protein interaction network. AIDS Res Hum Retroviruses 24, 1497–1502.[CrossRef][Medline]
Pugliese, A., Vidotto, V., Beltramo, T., Petrini, S. & Torre, D. (2005). A review of HIV-1 Tat protein biological effects. Cell Biochem Funct 23, 223–227.[CrossRef][Medline]
Pumfery, A., Deng, L., Maddukuri, A., de-la-Fuente, C., Li, H., Wade, J. D., Lambert, P., Kumar, A. & Kashanchi, F. (2003). Chromatin remodeling and modification during HIV-1 Tat-activated transcription. Curr HIV Res 1, 343–362.[CrossRef][Medline]
Ramalingam, S., Kannangai, R., Abraham, O. C., Subramanian, S., Rupali, P., Pulimood, S. A., Jesudason, M. V. & Sridharan, G. (2008). Investigation of apoptotic markers among human immunodeficiency virus (HIV-1) infected individuals. Indian J Med Res 128, 728–733.[Medline]
Richman, D. D., Margolis, D. M., Delaney, M., Greene, W. C., Hazuda, D. & Pomerantz, R. J. (2009). The challenge of finding a cure for HIV infection. Science 323, 1304–1307.
Rohr, O., Marban, C., Aunis, D. & Schaeffer, E. (2003). Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. J Leukoc Biol 74, 736–749.
Romani, B. & Engelbrecht, S. (2009). Human immunodeficiency virus type 1 Vpr: functions and molecular interactions. J Gen Virol 90, 1795–1805.
Rossi, A., Mukerjee, R., Ferrante, P., Khalili, K., Amini, S. & Sawaya, B. E. (2006). Human immunodeficiency virus type 1 Tat prevents dephosphorylation of Sp1 by TCF-4 in astrocytes. J Gen Virol 87, 1613–1623.
Ruwanpura, S. M., McLachlan, R. I., Stanton, P. G. & Meachem, S. J. (2008). Follicle-stimulating hormone affects spermatogonial survival by regulating the intrinsic apoptotic pathway in adult rats. Biol Reprod 78, 705–713.
Samuel, C. E. (2006). Virus-host interaction minireview series: human immunodeficiency virus, hepatitis C virus, and influenza virus. J Biol Chem 281, 8305–8307.
Sawaya, B. E., Khalili, K., Gordon, J., Taube, R. & Amini, S. (2000). Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome. J Biol Chem 275, 35209–35214.
Scala, G., Ruocco, M. R., Ambrosino, C., Mallardo, M., Giordano, V., Baldassarre, F., Dragonetti, E., Quinto, I. & Venuta, S. (1994). The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med 179, 961–971.
Schwarze, S. R. & Dowdy, S. F. (2000). In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci 21, 45–48.[CrossRef][Medline]
Schwarze, S. R., Ho, A., Vocero-Akbani, A. & Dowdy, S. F. (1999). In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285, 1569–1572.
Schwarze, S. R., Hurska, K. A. & Dowdy, S. F. (2000). Protein transduction: unrestricted delivery into all cells. Trends Cell Biol 10, 290–295.[CrossRef][Medline]
Siegelin, M. D., Reuss, D. E., Habel, A., Rami, A. & von-Deimling, A. (2009). Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro-oncol 11, 122–131.
Sodhi, A., Montaner, S. & Gutkind, J. S. (2004). Viral hijacking of G-protein coupled-receptor signalling networks. Nat Rev Mol Cell Biol 5, 998–1012.[CrossRef][Medline]
Stettner, M. R., Nance, J. A., Wright, C. A., Kinoshita, Y., Kim, W. K., Morgello, S., Rappaport, J., Khalili, K., Gordon, J. & Johnson, E. M. (2009). SMAD proteins of oligodendroglial cells regulate transcription of JC virus early and late genes coordinately with the Tat protein of human immunodeficiency virus type 1. J Gen Virol 90, 2005–2014.
Subramanian, M., Pilli, T., Bhattacharya, P., Pacini, F., Nikiforov, Y. E., Kanteti, P. V. & Prabhakar, B. S. (2009). Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis. J Clin Endocrinol Metab 94, 1467–1471.
Sun, Y., Huang, Y. C., Xu, Q. Z., Wang, H. P., Bai, B., Sui, J. L. & Zhou, P. K. (2006). HIV-1 Tat depresses DNA-PKCs expression and DNA repair, and sensitizes cells to ionizing radiation. Int J Radiat Oncol Biol Phys 65, 842–850.[Medline]
Tarasenko, T., Kole, H. K., Chi, A. W., Mentink-Kane, M. M., Wynn, T. A. & Bolland, S. (2007). T cell-specific deletion of the inositol phosphatase SHIP reveals its role in regulating Th1/Th2 and cytotoxic responses. Proc Natl Acad Sci U S A 104, 11382–11387.
Tian, R.-r., Liano, Q.-J. & Chen, X. (2008). Prevention and treatment of KSHV-associated diseases with antiviral drugs. Virol Sin 23, 486–495.[CrossRef]
Toda, T., Nakamura, M., Morisawa, H. & Hirota, M. (2007). Proteomic identification of oxidative-stress-reporting biomarkers differentially secreted from human neuroblastoma SH-SY5Y cells. J Electrophoresis 51, 21–26.[CrossRef]
Toschi, E., Bacigalupo, I., Strippoli, R., Chiozzini, C., Cereseto, A., Falchi, M., Nappi, F., Sgadari, C., Barillari, G. & other authors (2006). HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway. Mol Biol Cell 17, 1985–1994.
Tournier, J. N. & Quesnel-Hellmann, A. (2006). Host-pathogen interactions: a biological rendez-vous of the infectious nonself and danger models. PLoS Pathog 2, E44[CrossRef][Medline]
Turchan, J., Pocernich, C. B., Gairola, C., Chauhan, A., Schifitto, G., Butterfield, D. A., Buch, S., Narayan, O., Sinai, A. & other authors (2003). Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology 60, 307–314.
Turner, M. A. & Palefsky, J. M. (1998). HIV-1 Tat protein increases invasion of human papillomavirus type 16 positive keratinocytes. J Acquir Immune Defic Syndr 17, A13
Turpin, J. A. (2003). The next generation of HIV/AIDS drugs: novel and developmental anti HIV drugs and targets. Expert Rev Anti Infect Ther 1, 97–128.[CrossRef][Medline]
Tyagi, M., Rusnati, M., Presta, M. & Giacca, M. (2001). Internalization of HIV-1 Tat requires cell surface heparin sulfate proteoglycans. J Biol Chem 276, 3254–3261.
Vashistha, H., Husain, M., Kumar, D. & Singhal, P. C. (2009). Tubular cell HIV-1 gp120 expression induces caspase 8 activation and apoptosis. Ren Fail 31, 303–312.[CrossRef][Medline]
Vendeville, A., Rayne, F., Bonhoure, A., Bettache, N., Montcourrier, P. & Beaumelle, B. (2004). HIV-1 Tat enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responses. Mol Biol Cell 15, 2347–2360.
Wallace, D. R., Dodson, S. L., Nath, A. & Booze, R. M. (2005). Delta opioid agonists attenuate TAT1–72-induced oxidative stress in SK-N-SH cells. Neurotoxicology 27, 101–107.[CrossRef][Medline]
Westendorp, M. O., Li-Weber, M., Frank, R. W. & Krammeri, P. H. (1994). Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J Virol 68, 4177–4185.
Williams, S. A., Chen, L. F., Kwon, H., Ruiz-Jarabo, C. M., Verdin, E. & Greene, W. C. (2006). NF-B p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 25, 139–149.[CrossRef][Medline]
Wong, K., Sharma, A., Awasthi, S., Matlock, E. F., Rogers, L., Lint, C. V., Skiest, D. J., Burns, D. K. & Harrod, R. (2005). HIV-1 Tat interactions with p300 and PCAF transcriptional coactivators inhibit histone acetylation and neurotrophin signaling through CREB. J Biol Chem 280, 9390–9399.
Yedavalli, V. S. R. K., Benkirane, M. & Jeang, K. T. (2003). Tat and trans-activation-responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1. J Biol Chem 278, 6404–6410.
Zagury, D., Lachgar, A., Chams, V., Fall, L. S., Bernard, J., Zagury, J. F., Bizzini, B., Gringeri, A., Santagostini, E. & other authors (1998). Interferon and Tat involvement in the immunosuppression of uninfected T cells and C–C chemokine decline in AIDS. Proc Natl Acad Sci U S A 95, 3851–3856.
Zauli, G., Milani, D., Mirandola, P., Mazzoni, M., Secchiero, P., Miscia, S. & Capitani, S. (2001). HIV-1 Tat protein down-regulates CREB transcription factor expression in PC12 neuronal cells through a phosphatidylinositol 3-kinase/AKT/cyclic nucleoside phosphodiesterase pathway. FASEB J 15, 483–491.
Zhang, M., Li, X., Pang, X., Ding, L., Wood, O., Clouse, K. A., Hewlett, I. & Dayton, A. I. (2002). Bcl-2 upregulation by HIV-1 Tat during infection of primary human macrophages in culture. J Biomed Sci 9, 133–139.[CrossRef][Medline]
Zhao, T., Adams, M. H., Zou, S. P., El-Hage, N., Hauser, K. F. & Knapp, P. E. (2007). Silencing the PTEN gene is protective against neuronal death induced by human immunodeficiency virus type 1 Tat. J Neurovirol 13, 97–106.[CrossRef][Medline]
Zheng, L., Yang, Y. D., Lu, G. C. & Salvato, M. S. (2005). Extracellular HIV Tat and Tat cysteine rich peptide increase CCR5 expression in monocytes. J Zhejiang Univ Sci B 6, 668–672.[Medline]
Zheng, L., Yang, Y., Guocai, L., Pauza, C. D. & Salvato, M. S. (2007). HIV Tat protein increases Bcl-2 expression in monocytes which inhibits monocyte apoptosis induced by tumor necrosis factor-alpha-related apoptosis-induced ligand. Intervirology 50, 224–228.[CrossRef][Medline]
Zhou, M., Deng, L., Kashanchi, F., Brady, J. N., Shatkin, A. J. & Kumar, A. (2003). The Tat/TAR-dependent phosphorylation of RNA polymerase II C-terminal domain stimulates cotranscriptional capping of HIV-1 mRNA. Proc Natl Acad Sci U S A 100, 12666–12671.
Zuo, Y., Matsusaka, T., Zhong, J., Ma, J., Ma, L. J., Hanna, Z., Jolicoeur, P., Fogo, A. B. & Ichikawa, I. (2006). HIV-1 genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis. J Am Soc Nephrol 17, 2832–2843.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
TOP
ABSTRACT
Introduction
